Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Trimi vs The Aesthetic Concierge

Two GLP-1 desks, one scoreboard. We put Trimi and The Aesthetic Concierge head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 2 · Grade B+

Trimi

Visit Trimi Full brief →
vs
No. 63 · Grade C

The Aesthetic Concierge

Visit The Aesthetic Concierge Full brief →

The verdict

Trimi takes this head-to-head.

Trimi scores 89 to 77 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.

That doesn't make The Aesthetic Concierge a bad call — it's best for people who want physician-led, legitscript-verified glp-1 care with concierge support. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
78
Supply Reliability
89
77
Transparency
91
88
Access Breadth
89
54
Clinical Oversight
88
83
Track Record
84
79
TrimiBrief Score 89 · 77The Aesthetic Concierge

Price, coverage & the tracker

TrimiThe Aesthetic Concierge
Brief Score89/100 (B+)77/100 (C)
Semaglutide$196/mo$414/mo
Tirzepatide$296/moNot disclosed
CoverageAll 50 states13 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.

The Aesthetic Concierge: New to the tracker on 1 August 2026. The published line reads $414/mo at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.